All In Biotech

Drug Trial Radar · NCT07876817

A Prospective, Multi-Center, Phase 4, Single Arm Study To Assess The Safety and Tolerability of Perioperative Durvalumab in Combination With Neoadjuvant Gemcitabine Plus Cisplatin in Indian Patients With Muscle-Invasive Bladder Cancer Cle-Invasive

A Prospective, Multi-Center, Phase 4, Single Arm Study To Assess The Safety and Tolerability of Perioperative Durvalumab in Combination With Neoadjuvant Gemcitabine Plus Cisplatin in Indian Patients With Muscle-Invasive Bladder Cancer (MIBC).

Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Oct 20, 2026

Primary completion

Jan 31, 2029

Study completion Jan 31, 2029

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Oct 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 4, Single Arm Study To Assess The Safety and tolerability of Perioperative Durvalumab in Combination with Neoadjuvant Gemcitabine Plus Cisplatin Treatment Followed by radical cystectomy and Durvalumab alone as Treatment in Indian Patients with Muscle-Invasive Bladder Cancer. It is to be conducted in compliance with a condition of approval specified by Health Authority of India following the addition of this indication to the approved prescribing information. A phase IV clinical trial to Asses the safety profile of this regimen in patients from India and subsequently, any regulatory action resulting from the review should be complied.

Conditions

  • Muscle-Invasive Bladder Cancer (MIBC)

Interventions

  • DurvalumabDrug

    Solution for IV infusion, 1500 mg/vial. Administered at 1500 mg IV every 3 weeks during the neoadjuvant phase and every 4 weeks during the adjuvant phase.

  • GemcitabineDrug

    Solution for IV infusion. Administered at 1000 mg/m² on Day 1 and Day 8 of each 21-day neoadjuvant cycle.

  • CisplatinDrug

    Solution for IV infusion. Administered at 70 mg/m² on Day 1 of each 21-day neoadjuvant cycle. A split dose of 35 mg/m² on Days 1 and 8 may be used for patients with borderline renal function.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of subjects experiencing adverse events (AEs)Time frame: Throughout the study, up to approximately 66 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.